论文部分内容阅读
本文应用全国脑防办双盲编号的国产降纤酶静滴治疗发病24h以内的急性脑梗塞病人34例．降纤酶治疗组21例，对照组13例．在应用降纤酶治疗前进行神经功能缺损评分．在出院时和第12周进行两次病人日常生活功能的评估（Barthel氏指数）．并同时于治疗前、后检测血浆中纤维蛋白原含量、肝功、肾功．研究结果显示，近期疗效降纤酶治疗组优于对照组，神经功能缺损评分进步亦优于对照组，但不具备统计学显著性差异（P＞005）．病人第12周日常生活能力评估（Barthel氏指数）较出院时有显著进步（P＜0．001）。研究显示国产降纤酶确为有效降低血浆纤维蛋白原的药物，对急性脑梗塞治疗有一定的疗效．
In this paper, the National Brain Prevention Office double-blind number of domestic defibrinated enzyme intravenous drip treatment of onset within 24 hours of acute cerebral infarction in 34 patients. Defibrase treatment group 21 cases, control group 13 cases. Neurological deficit scores were assessed before defibrase treatment. The patient’s daily living function was assessed twice (Barthel’s index) at discharge and at week 12. At the same time in the treatment before and after testing the plasma fibrinogen content, liver function, kidney function. The results show that the recent treatment of defibrase in the treatment group than the control group, neurological deficit score is also better than the control group, but not statistically significant difference (P> 005). The Barthel index at week 12 was significantly higher (P <0.001) than at discharge. Studies have shown that domestic defibrase is indeed an effective drug to reduce plasma fibrinogen, which has certain curative effect on the treatment of acute cerebral infarction.